Wednesday, April 7, 2010 as of 11:14 AM ET
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010.
Read More at Wikipedia ›
Major drug makers are reportedly working with European authorities on an emergency plan that would keep medicines flowing to Greece if the embattled country exits the eurozone.
Discussions have intensified in recent days, according to a report by Reuters, as regulators fear an exit may be imminent.The talks, which include analyzing a similar experience in Argentina during its collapse in 2002, when some firms agreed to continue the supply of medicines temporarily without payment, is an effort to avoid a potential heath catastrophe should medical imports stop altogether.The idea is to have an easy way to implement a short-term solution that would maintain the flow of medicines over a few months as the country falls out of the eurozone, a source close to the matter told Reuters.Greece imports all of its medicines, with particular reliance on brand-name drugs, such as those made by European drug makers Novartis (NYSE:NVS), Roche, GlaxoSmithKline (NYSE:GSK) and AstraZeneca (NYSE:AZN), as op...An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the...
The U.S. Food and Drug Administration said that the treatment effect from a proposed Regeneron Pharmaceuticals Inc. (REGN) treatment for gout was "small," and the ag...
The boom in Switzerland's property market extended into the first quarter, driven by record low mortgage rates and the ongoing influx of cash-rich migrants, and is s...
Novartis AG (NVS, NOVN.VX) signed a definitive agreement to acquire New York-based specialty dermatology generics company Fougera Pharmaceuticals for $1.53 billion i...
DOW JONES NEWSWIRESEndo Pharmaceuticals Holdings Inc.'s (ENDP) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation sett...
(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)Patients with soft-tissue sarcoma, a rare cancer that sta...
French drugs giant Sanofi SA (SNY) on Friday reported higher sales and profits for the first quarter but maintained its pessimistic outlook for earnings to fall as m...
DOW JONES NEWSWIRESFinnish pharmaceutical company Orion Corp. (ORNBV.HE) said late Thursday it has filed a patent infringement lawsuit in the United States to enforc...
The U.S. Food and Drug Administration Thursday granted wider approval to Novartis AG's (NVS, NOVN.VX) Afinitor to treat non-cancerous kidney tumors that don't requir...
The U.K.'s health-cost regulator is backing Novartis's (NVS) pill Gilenya for certain adult patients with highly active relapsing-remitting multiple sclerosis.The in...
The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-bas...
On a trading day that saw the S&P 500 gain 0.4%, the Health Care sector (XLV) showed little change.While being down today, the ETF, as a proxy for sector performance...
The FDA says the only oral multiple-sclerosis drug on the market -- Novartis's Gilenya -- shouldn't be used in patients with a recent history of stroke or some heart...
WBI Funds CEO Don Schreiber on the outlook for the U.S. financial sector.
The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of...
Multinational and Indian pharmaceutical companies Thursday refuted the findings of a probe conducted by Indian lawmakers which said they violated rules governing app...
European stocks pushed firmly into the red on Thursday, with downbeat data from China adding to political worries in Europe. Drug, food and beverage and oil sectors ...
GlaxoSmithKline PLC (GSK) said Thursday the company was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial...
The U.K.'s publicly-funded National Health Service could save GBP84.5 million a year if it replaced a Novartis-marketed (NVS) treatment for a common eye disease in e...
Quotes delayed at least 15 minutes. Real-time quotes provided by BATS Exchange. Market Data provided by Interactive Data (Terms & Conditions). Powered and Implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.
This material may not be published, broadcast, rewritten, or redistributed. ©2012 FOX News Network, LLC. All rights reserved.
